Only 40–60% of women with HER2-positive breast cancers will achieve a complete pathological response to standard regimens of chemotherapy combined with either trastuzumab alone or with trastuzumab plus pertuzumab [10,11,12,13,14,15,16,17,18,19]. Here, ERBB2 is linked to breast carcinoma.